ProCE Banner Activity

Advances and Recent Approvals for Immunotherapy and Targeted Therapies in Cervical Cancer

Clinical Thought
Read this commentary from Ritu Salani, MD, MBA, with her thoughts on recent advances and approvals for immunotherapy-based combinations and targeted therapies in cervical cancer.

Released: February 18, 2022

Expiration: February 17, 2023

Share

Faculty

Ritu Salani

Ritu Salani, MD, MBA

Professor and Division Director
OB/GYN and Gynecologic Oncology
University of California, Los Angeles
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

GlaxoSmithKline

Merck Sharp & Dohme Corp.

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme

Faculty Disclosure

Primary Author

Ritu Salani, MD, MBA

Professor and Division Director
OB/GYN and Gynecologic Oncology
University of California, Los Angeles
Los Angeles, California

Ritu Salani, MD, MBA, has disclosed that she has received consulting fees from Arcus, Genentech, GlaxoSmithKline, Instil Bio, Merck, and Seagen; research support from Regeneron.

Staff Disclosure

Staff

Jerfiz Constanzo, PhD, MBA

Scientific Director

Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista V. Marcello has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.